Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles.

Cardiovascular disease is one of the major contributors to global disease burden. Atherosclerosis is an inflammatory process that involves the accumulation of lipids and fibrous elements in the large arteries, forming an atherosclerotic plaque. Rupture of unstable plaques leads to thrombosis that triggers life-threatening complications such as myocardial infarction. Current diagnostic methods are invasive as they require insertion of a catheter into the coronary artery. Molecular imaging techniques, such as magnetic resonance imaging, have been developed to image atherosclerotic plaques and thrombosis due to its high spatial resolution and safety. The sensitivity of magnetic resonance imaging can be improved with contrast agents, such as iron oxide nanoparticles. This review presents the most recent advances in atherosclerosis, thrombosis, and myocardial infarction molecular imaging using iron oxide-based nanoparticles. While some studies have shown their effectiveness, many are yet to undertake comprehensive testing of biocompatibility. There are still potential hazards to address and complications to diagnosis, therefore strategies for overcoming these challenges are required.

Investigating the Use of Layered Double Hydroxide Nanoparticles as Carriers of Metal Oxides for Theranostics of ROS-Related Diseases.

Overproduction of reactive oxygen species (ROS) is commonly known as a key factor in the progression of many chronic inflammation diseases such as atherosclerosis and rheumatoid arthritis. In this study, a metal oxide nanodot-coated layered double hydroxide (LDH) nanocomposite is constructed for theranostics of ROS-related diseases. This is the first time that both cerium oxide and iron oxide nanoparticles (NPs) were attached on the surface of LDH NPs through electrostatic interaction via a nanoengineering approach. LDHs served as nanocarriers, cerium oxide NPs served as therapeutic agents due to the antioxidant properties, and iron oxide NPs served as magnetic resonance imaging (MRI) contrast agents. In vitro studies have demonstrated that the constructed nanocomposites have good biocompatibility, good antioxidant capacity to reduce ROS level in the cells, as well as satisfying cell imaging effect in MRI. Functionalization of LDH surface with cerium oxide NPs and iron oxide NPs allows the simultaneous therapy and diagnosis of ROS-related diseases and may also allow biodistribution tracking of the therapeutic cerium oxide NPs.